Shares of Masimo Co. (NASDAQ:MASI) have received an average recommendation of “Hold” from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $97.17.
Several analysts recently commented on the stock. Zacks Investment Research downgraded shares of Masimo from a “buy” rating to a “hold” rating in a research report on Tuesday, October 3rd. BidaskClub downgraded shares of Masimo from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. Finally, Stifel Nicolaus restated a “buy” rating and set a $108.00 price objective on shares of Masimo in a research report on Friday, November 3rd.
In other news, EVP Yongsam Lee sold 5,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $89.89, for a total transaction of $449,450.00. Following the transaction, the executive vice president now directly owns 74,000 shares of the company’s stock, valued at approximately $6,651,860. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Steven Barker sold 10,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $90.00, for a total transaction of $900,000.00. Following the transaction, the director now directly owns 73,249 shares in the company, valued at $6,592,410. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 53,074 shares of company stock valued at $4,737,245. 13.10% of the stock is owned by insiders.
Large investors have recently bought and sold shares of the company. DekaBank Deutsche Girozentrale grew its stake in shares of Masimo by 78.3% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 2,106 shares of the medical equipment provider’s stock worth $182,000 after purchasing an additional 925 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Masimo by 13.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,018 shares of the medical equipment provider’s stock worth $184,000 after purchasing an additional 236 shares during the period. Advisor Group Inc. grew its stake in shares of Masimo by 38.4% during the 2nd quarter. Advisor Group Inc. now owns 2,361 shares of the medical equipment provider’s stock worth $216,000 after purchasing an additional 655 shares during the period. Intellectus Partners LLC acquired a new position in shares of Masimo during the 2nd quarter worth $237,000. Finally, Shelton Capital Management acquired a new position in shares of Masimo during the 2nd quarter worth $269,000. 83.69% of the stock is currently owned by institutional investors and hedge funds.
Shares of Masimo (MASI) opened at $85.70 on Friday. Masimo has a 12-month low of $66.79 and a 12-month high of $104.71. The company has a market cap of $4,430.00, a price-to-earnings ratio of 13.58, a P/E/G ratio of 2.91 and a beta of 0.72.
Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, October 31st. The medical equipment provider reported $0.70 EPS for the quarter, beating the consensus estimate of $0.53 by $0.17. Masimo had a net margin of 20.26% and a return on equity of 22.06%. The firm had revenue of $193.69 million during the quarter, compared to the consensus estimate of $189.01 million. During the same quarter in the prior year, the firm earned $0.52 EPS. Masimo’s revenue for the quarter was up 15.6% on a year-over-year basis. analysts expect that Masimo will post 2.95 earnings per share for the current year.
WARNING: This piece was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://ledgergazette.com/2018/01/13/masimo-co-masi-receives-consensus-rating-of-hold-from-analysts.html.
Masimo Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.